SOX2-OT and osteosarcoma: It was demonstrated that high SOX2OT expression is associated with the poor survival/prognosis of patients with lung cancer [122], gastric cancer [123,124], hepatocellular carcinoma [125,126], ovarian cancer [127], pancreatic ductal adenocarcinoma [6], cholangiocarcinoma [116], osteosarcoma [117], nasopharyngeal carcinoma [128], bladder cancer [119] and prostate cancer [129].